CLINICAL IMMUNOLOGY
Antiphospholipid antibodies in patients with upper-extremity deep vein thrombosis
Submission date: 2015-03-06
Final revision date: 2015-04-14
Acceptance date: 2015-05-08
Publication date: 2015-10-15
Cent Eur J Immunol 2015;40(3):307-310
KEYWORDS
ABSTRACT
The levels of antibodies to cardiolipin and 2-glycoprotein I and polymorphic variants G1691A of Factor V (factor V Leiden, FVL) and G20210A of prothrombin gene (G20210A) were studied in 16 patients with upper-extremity deep vein thrombosis (UEDVT). Most of patients with this syndrome have elevated values of these antibodies. Two of these patients are heterozygous carriers for G20210A and 1 – for FVL. Three patients with UEDVT and systemic lupus erythematosus (SLE) are positive for ANA and two others (one of them with Raynaud syndrome) have border line titre 1 : 80 for ANA. All 3 patients with SLE are women and the interval between the development of the UEDVT and the onset of SLE was 1-4 years. We would like to suggest that: 1) UEDVT could be the first clinical symptom of Antiphospholipid syndrome, and 2) UEDVT may be the first clinical manifestation of SLE preceding the development of the systemic autoimmune disease by several years.
REFERENCES (25)
1.
Kucher N (2011): Clinical practice. Deep-vein thrombosis of the upper extremities. N Engl J Med 364: 861-869.
2.
Zell L, Sommerfeld A, Bucher A (1999): Das Paget – von Schroetter Syndrom: Ein Beitrag zum 100. Todesjahr von Sir James Paget und zur 50-jährigen Namensgebung des Syndroms. DeutschMed Woch 124: 948-951.
3.
Drapanas T, Curran WL (1966): Thrombectomy in the treatment of “effort” thrombosis of the axillary and subclavian veins. J Trauma 6: 107.
4.
Zell L, Kindermann W, Marschall F, et al. (2001): Paget - Schroetter syndrome in sports activities-case study and literature review. Angiology 52: 337-342.
5.
Moinat CH, Periard D, Grueber A, et al. (2014): Predictirs of venous thromboembolic events associated with central venous port insertion in cancer patients. J Oncology http//dx.doi.org/10.1155/2014/743181.
6.
Joffe HV, Goldhaber SZ (2002): Upper-extremity deep vein thrombosis. Circulation 106: 1874-1880.
7.
Miyakis S, Lockshin M, Atsumi T, et al. (2006): International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome. J Thrombosis Haemost 4: 295-306.
8.
Heron E, Lozinguez O, Alhenc-Gelas M, et al. (2000): Hypercoagulable states in primary upper-extremity deep vein thrombosis. Arch Int Med 160: 382-386.
9.
Prandoni P, Polistena P, Bernardi E, et al. (1997): Upper-extremity deep vein thrombosis risk factors, diagnosis and complications. Arch Int Med 157: 57-62.
10.
Martinelli I, Battaglioli T, Bucciarelli P, et al. (2004): Risk factors and recurrence rate of primary deep vein thrombosis of the upper extremities. Circulation 110: 566-576.
11.
Ruggeri M, Castaman G, Tosseto A, Rodeghiero F (1997): Low prevalence of thrombophilia coagulation defects in patients with deep vein thrombosis of the upper limbs. Blood Coagul Fibrinol 8: 191-194.
12.
Leebeek FWG, Stadhouders NAM, van Stein D, et al. (2001): Hypercoagulability states in upper-extremity deep vein thrombosis. Am J Hematol 67: 15-19.
13.
Petri M. Epidemiology of the antiphospholipid antibody syndrome (2000): J Autoimmunity 15: 145-151.
14.
Brower J-L P, Bijl M, Veeger NJGM, et al. (2004): The contribution of inherited and acquired thrombophilic defects, alone or combined with antiphospholipid antibodies, to venous and arterial thromboembolism in patients with systemic lupus erythematosus. Blood 104: 143-148.
15.
Cervera R, Piette J-M, Font J, et al. (2002): Antiphospholipid syndrome. Clinical and Immunologic Manifestations and Patterns of disease expression in a cohort of 1000 patients. Arthr Rheum 46: 1019-1027.
16.
Chang ER, Pineau C, Bernatsky S, et al. (2006): Risk for incident arterial or venous vascular events varies over the course of systemic lupus erythematosus. J Rheumatol 33: 1780-1784.
17.
Rees DC, Cox M, Clegg JB (1995): World distribution of factor V Leiden. Lancet: 346: 1133-1134.
18.
Boyanovsky B, Russeva M, Ganev V, et al. (2001): Prevalence of factor V Leiden and prothrombin 20210 A variant in Bulgarian patients with pulmonary thromboembolism and deep venous thrombosis. Blood Coagul Fibrinol 12: 639-642.
19.
Afeltra A, Vadacca M, Conti L, et al. (2005): Thrombosis in Systemic Lupus Erythematosus: Congenital and Acquired Risk Factors. Arthr & Rheum (Arthritis Care & Research) 53: 452-459.
20.
Topaloglu R, Akierli C, Bakkaloglu A, et al. (2001): Survey of factor V leiden and prothrombin gene mutations in systemic lupus erythematosus. Clin Rheumatol 20: 259-261.
21.
Regéczy N, Lakos G, Balogh I, et al. (2000): The Leiden mutation of coagulation factor V in Hungarian SLE patients. Clin Appl Thromb Hemost 6: 41-45.
22.
Barcat D, Gue`rin V, Ryman A, et al. (2003): Thrombophilia and thrombosis in systemic lupus erythematosus: a case-control study. Ann Rheum Dis 62: 1016-1017.
23.
Boyanovsky B, Russeva M, Ganev V, et al. (2000): Antiphospholipid syndrome, factor V Leiden and and activity of protein C – causes for thromboses in patients with systemic lupus erythematosus. Rheumatology 8: 30-34 (in Bulgarian, English abstract).
24.
Bertolaccini ML, Amengual O, Andreoli L, et al. (2014): 14th International congress of antiphospholipid antibodies task force. Report on antiphospholipid syndrome laboratory diagnostics and trends. Autoimmun Rev 13: 917-930.
25.
Engelberger RP, Kucher N (2012): Management of deep vein thrombosis of the upper extremity. Circulation 126: 768-773.
Share
RELATED ARTICLE
| eISSN: | 1644-4124 |
| ISSN: | 1426-3912 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
